{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:56:06Z","timestamp":1789448166436,"version":"build-2803163510"},"reference-count":64,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The treatment landscape of classical Hodgkin lymphoma has changed dramatically over the past decade. Relapsed and refractory mainstay therapeutics such as brentuximab vedotin (BV) and checkpoint inhibitors (CPIs) are being moved to earlier lines of therapy. However, the treatment of patients who progress after BV and CPI remains a challenge. Allogeneic stem cell transplantation still plays an important role in this patient population as the only current treatment approach with curative potential. Unfortunately, not all patients are transplant candidates, and many will still relapse afterward. Cytotoxic chemotherapy and radiation may be used for symptom palliation or as a bridge to transplant. Targeted therapies, including the antibody drug conjugate, camidanlumab tesirine, and transcriptional agents such mammalian target of rapamycin and histone deacetylase inhibitors have shown some potential in patients with refractory disease. In addition, combination therapies with CPIs and novel agents may help overcome resistance to therapy. Clinical trials with cellular therapies, including chimeric antigen receptor T cells targeting CD30 and allogeneic natural killer cells combined with AFM13, a CD30\/CD16a-bispecific antibody, have shown promising results. The availability of more therapeutic options for this patient population is eagerly awaited.<\/jats:p>","DOI":"10.1182\/hematology.2023000450","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:12:28Z","timestamp":1702048348000},"page":"510-518","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["The optimal management of relapsed and refractory Hodgkin lymphoma: post\u2013brentuximab and checkpoint inhibitor failure"],"prefix":"10.1182","volume":"2023","author":[{"given":"Natalie S.","family":"Grover","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dittus","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astha","family":"Thakkar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne W.","family":"Beaven","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"4","key":"2023120815072842900_hem2023000450C1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"2023120815072842900_hem2023000450C2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2000.18.2.332","article-title":"Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?","volume":"18","author":"Josting","year":"2000","journal-title":"J Clin Oncol"},{"issue":"6","key":"2023120815072842900_hem2023000450C3","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma","author":"Rancea","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2023120815072842900_hem2023000450C4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"31","key":"2023120815072842900_hem2023000450C5","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"2023120815072842900_hem2023000450C6","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2023120815072842900_hem2023000450C7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00277-021-04429-8","article-title":"Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma","volume":"100","author":"Fedorova","year":"2021","journal-title":"Ann Hematol"},{"key":"2023120815072842900_hem2023000450C8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"10","key":"2023120815072842900_hem2023000450C9","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"issue":"14","key":"2023120815072842900_hem2023000450C10","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"2023120815072842900_hem2023000450C11","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdg496","article-title":"Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Baetz","year":"2003","journal-title":"Ann Oncol"},{"issue":"6","key":"2023120815072842900_hem2023000450C12","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Cancer Leukemia Group B. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol"},{"issue":"3","key":"2023120815072842900_hem2023000450C13","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"issue":"10","key":"2023120815072842900_hem2023000450C14","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","article-title":"Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease","volume":"13","author":"Josting","year":"2002","journal-title":"Ann Oncol"},{"issue":"25","key":"2023120815072842900_hem2023000450C15","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood"},{"issue":"28","key":"2023120815072842900_hem2023000450C16","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"2023120815072842900_hem2023000450C17","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S2352-3026(21)00170-8","article-title":"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase \u00bd study","volume":"8","author":"Lynch","year":"2021","journal-title":"Lancet Haematol"},{"issue":"10","key":"2023120815072842900_hem2023000450C18","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1634\/theoncologist.2020-0167","article-title":"Checkpoint blockade treatment may sensitize Hodgkin lymphoma to subsequent therapy","volume":"25","author":"Carreau","year":"2020","journal-title":"Oncologist"},{"issue":"13","key":"2023120815072842900_hem2023000450C19","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2000.18.13.2615","article-title":"Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study","volume":"18","author":"Santoro","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023120815072842900_hem2023000450C20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.1998.16.2.584","article-title":"Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant","volume":"16","author":"Little","year":"1998","journal-title":"J Clin Oncol"},{"issue":"4","key":"2023120815072842900_hem2023000450C21","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","author":"Moskowitz","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023120815072842900_hem2023000450C22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.12120","article-title":"Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma","volume":"160","author":"Corazzelli","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"2023120815072842900_hem2023000450C23","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.ijrobp.2012.04.007","article-title":"Role of salvage radiation therapy for patients with relapsed or refractory Hodgkin lymphoma who failed autologous stem cell transplant","volume":"84","author":"Goda","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2023120815072842900_hem2023000450C24","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","article-title":"The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Constine","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"2023120815072842900_hem2023000450C25","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2023120815072842900_hem2023000450C26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2015.332","article-title":"Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis","volume":"51","author":"Rashidi","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2023120815072842900_hem2023000450C27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","article-title":"Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Sureda","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"2023120815072842900_hem2023000450C28","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/bmt.2016.349","article-title":"Reduced-intensity and non- myeloablative allogeneic stem cell transplantation from alternative HLA- mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy","volume":"52","author":"Gauthier","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2023120815072842900_hem2023000450C29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2991\/chi.k.210704.002","article-title":"The impact of achieving complete remission prior to allogeneic stem cell transplantation on progression-free survival in Hodgkin lymphoma","volume":"3","author":"Durakovi\u0107","year":"2021","journal-title":"Clin Hematol Int"},{"issue":"11","key":"2023120815072842900_hem2023000450C30","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1038\/s41409-021-01396-6","article-title":"Immune checkpoint inhibitors and allogeneic transplant in lymphoid malignancies: a deceptive friend story","volume":"56","author":"Farttoosi","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2023120815072842900_hem2023000450C31","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(21)00103-4","article-title":"Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study","volume":"8","author":"Hamadani","year":"2021","journal-title":"Lancet Haematol"},{"key":"2023120815072842900_hem2023000450C32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.HS9.0000843696.37630.1c","article-title":"S201: camidanlumab tesirine: updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R\/R CHL)","volume":"6","author":"Carlo-Stella","year":"2022","journal-title":"HemaSphere"},{"issue":"16, suppl","key":"2023120815072842900_hem2023000450C33","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.1200\/JCO.2022.40.16_suppl.7545","article-title":"Favezelimab (anti\u2013LAG-3) plus pembrolizumab in patients with relapsed or refractory (R\/R) classical Hodgkin lymphoma (cHL) after anti\u2013PD-1 treatment: an open-label phase 1\/2 study","volume":"40","author":"Timmerman","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"2023120815072842900_hem2023000450C34","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase \u00bd trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol"},{"issue":"19","key":"2023120815072842900_hem2023000450C35","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","article-title":"A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger","year":"2011","journal-title":"Blood"},{"key":"2023120815072842900_hem2023000450C36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40164-018-0103-z","article-title":"Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma","volume":"7","author":"Johnston","year":"2018","journal-title":"Exp Hematol Oncol"},{"issue":"7","key":"2023120815072842900_hem2023000450C37","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.3324\/haematol.2021.278853","article-title":"Phase I\/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas","volume":"107","author":"Major","year":"2022","journal-title":"Haematologica"},{"issue":"18","key":"2023120815072842900_hem2023000450C38","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in patients with relapsed\/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2023120815072842900_hem2023000450C39","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3324\/haematol.10797","article-title":"Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018)","volume":"92","author":"Trelle","year":"2007","journal-title":"Haematologica"},{"key":"2023120815072842900_hem2023000450C40","article-title":"Pembrolizumab plus vorinostat is highly active in Hodgkin lymphoma, including patients refractory to prior PD-1 blockade [published online June 20, 2023]","volume-title":"Blood","author":"Mei"},{"issue":"suppl 2","key":"2023120815072842900_hem2023000450C41","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/hon.3164_436","article-title":"Phase 1 trial of ruxolitinib combined with nivolumab in patients relapsed\/refractory Hodgkin lymphoma after failure of check-point inhibitor (CPI)","volume":"41","author":"Bachanova","year":"2023","journal-title":"Hematol Oncol"},{"issue":"5","key":"2023120815072842900_hem2023000450C42","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3390\/cancers15051437","article-title":"A phase 2 trial of ibrutinib and nivolumab in patients with relapsed or refractory classical Hodgkin's lymphoma","volume":"15","author":"Hanel","year":"2023","journal-title":"Cancers"},{"issue":"17","key":"2023120815072842900_hem2023000450C43","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"2023120815072842900_hem2023000450C44","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.3109\/10428194.2012.666543","article-title":"Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure","volume":"53","author":"Nathwani","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2023120815072842900_hem2023000450C45","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","article-title":"CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin","volume":"14","author":"Chen","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"32","key":"2023120815072842900_hem2023000450C46","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2023120815072842900_hem2023000450C47","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1182\/blood-2022-158869","article-title":"Updated results and correlative analysis: autologous CD30.CAR-T-Cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma (CHARIOT Trial)","volume":"140","author":"Ahmed","year":"2022","journal-title":"Blood"},{"issue":"25","key":"2023120815072842900_hem2023000450C48","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"issue":"suppl 1","key":"2023120815072842900_hem2023000450C49","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2021-148102","article-title":"CD30-directed CAR-T cells co- expressing CCR4 in relapsed\/refractory Hodgkin lymphoma and CD30+ cutaneous T cell lymphoma","volume":"138","author":"Grover","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023120815072842900_hem2023000450C50","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2022-167504","article-title":"Phase 1 clinical trial of memory-enriched academic HSP-CAR30 for the treatment of relapsed\/refractory Hodgkin lymphoma and CD30+ T-cell lymphoma: clinical and biological studies","volume":"140","author":"Caballero Gonzalez","year":"2022","journal-title":"Blood"},{"key":"2023120815072842900_hem2023000450C51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.858021","article-title":"Anti-PD-1 therapy enhances the efficacy of CD30-directed chimeric antigen receptor T cell therapy in patients with relapsed\/refractory CD30+ lymphoma","volume-title":"Front Immunol","author":"Sang","year":"2022"},{"issue":"suppl 1","key":"2023120815072842900_hem2023000450C52","doi-asserted-by":"crossref","first-page":"12723","DOI":"10.1182\/blood-2022-156660","article-title":"Clinical activity of anti-PD-1 therapy following CD30 CAR-T cell therapy in relapsed Hodgkin lymphoma","volume":"140","author":"Voorhees","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2023120815072842900_hem2023000450C53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.0.CO;2-T","article-title":"Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data","volume":"70","author":"Glaser","year":"1997","journal-title":"Int J Cancer"},{"issue":"8","key":"2023120815072842900_hem2023000450C54","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"2023120815072842900_hem2023000450C55","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma","volume":"36","author":"Bollard","year":"2018","journal-title":"J Clin Oncol"},{"issue":"13","key":"2023120815072842900_hem2023000450C56","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.20.02224","article-title":"T-cell therapy for lymphoma using nonengineered multiantigen-targeted T cells is safe and produces durable clinical effects","volume":"39","author":"Vasileiou","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"2023120815072842900_hem2023000450C57","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/bloodadvances.2021005343","article-title":"Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed\/refractory Hodgkin lymphoma","volume":"6","author":"Dave","year":"2022","journal-title":"Blood Adv"},{"issue":"suppl 2","key":"2023120815072842900_hem2023000450C58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/hon.3163_47","article-title":"Off-the-shelf CD30.CAR-modified Epstein-Barr virus-specific T cells (CD30.CAR EBVSTS) provide a safe and effective therapy for patients with Hodgkin lymphoma (HL)","volume":"41","author":"Ramos","year":"2023","journal-title":"Hematol Oncol"},{"issue":"26","key":"2023120815072842900_hem2023000450C59","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"issue":"suppl 1","key":"2023120815072842900_hem2023000450C60","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2022-156125","article-title":"Innate cell engager AFM13 combined with preactivated and expanded cord blood-derived NK cells for patients with double refractory CD30+ lymphoma","volume":"140","author":"Nieto","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023120815072842900_hem2023000450C61","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1182\/blood-2022-162231","article-title":"Safety and efficacy of tinostamustine in pre-treated patients with relapsed\/refractory (R\/R) Hodgkin lymphoma (HL): early results from an additional expansion cohort of a phase I study","volume":"140","author":"Sureda","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2023120815072842900_hem2023000450C62","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","article-title":"Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease","volume":"200","author":"Bollard","year":"2004","journal-title":"J Exp Med"},{"issue":"5","key":"2023120815072842900_hem2023000450C63","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2023120815072842900_hem2023000450C64","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/510\/2175884\/510grover.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/510\/2175884\/510grover.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:12:51Z","timestamp":1702048371000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/510\/506454\/The-optimal-management-of-relapsed-and-refractory"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000450","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}